2003
DOI: 10.1016/s0939-6411(03)00099-7
|View full text |Cite
|
Sign up to set email alerts
|

Protonation equilibrium and lipophilicity of olamufloxacin (HSR-903), a newly synthesized fluoroquinolone antibacterial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
14
0

Year Published

2006
2006
2012
2012

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 13 publications
(15 citation statements)
references
References 10 publications
1
14
0
Order By: Relevance
“…As with clinafloxacin, tosufloxacin 12, which was also withdrawn from the market, has a 3-amino-1-pyrrolidinyl radical in the 7-position. This useful substituent was modified by attaching additional small radicals, thus resulting in the more recent, highly active quinolones sitafloxacin (13; DU 6859) [80][81][82][83][84], DK-507 k 14 [85,86] and olamufloxacin (15; HSR 903) [87][88][89][90]containing an (S)-3-amino-1-pyrrolidinyl radical in the 7-position, to which a cyclopropyl radical is attached spirocyclically in the 4-position. Due to the omission of the Cl substituent in sitafloxacin from DK-507 k, the latter's phototoxic potential was reduced.…”
Section: The Chemical Evolution Of Moxifloxacinmentioning
confidence: 99%
See 3 more Smart Citations
“…As with clinafloxacin, tosufloxacin 12, which was also withdrawn from the market, has a 3-amino-1-pyrrolidinyl radical in the 7-position. This useful substituent was modified by attaching additional small radicals, thus resulting in the more recent, highly active quinolones sitafloxacin (13; DU 6859) [80][81][82][83][84], DK-507 k 14 [85,86] and olamufloxacin (15; HSR 903) [87][88][89][90]containing an (S)-3-amino-1-pyrrolidinyl radical in the 7-position, to which a cyclopropyl radical is attached spirocyclically in the 4-position. Due to the omission of the Cl substituent in sitafloxacin from DK-507 k, the latter's phototoxic potential was reduced.…”
Section: The Chemical Evolution Of Moxifloxacinmentioning
confidence: 99%
“…The effectiveness of moxifloxacin (MIC 90 0.06-0.125 mg L -1 ) against methicillin-sensitive S. aureus (MSSA) is four-to eight-fold greater than that of ciprofloxacin, ofloxacin, and levofloxacin, although its in vitro activity against methicillinresistant S. aureus (MRSA) is less powerful (MIC 90 182,187,188], although its activity against specific bacteria is less powerful than that of ciprofloxacin [188]. When moxifloxacin was used in combination with cefepime or piperacillin/tazobactam against clinical isolates of K. pneumoniae, Enterobacter cloacae and Acinetobacter baumannii, an increase in bactericidal activity was obtained compared to that of the individual compounds; this was due to synergistic effects between the different compounds [189].…”
Section: The Microbiological and Clinical Properties Of Moxifloxacinmentioning
confidence: 99%
See 2 more Smart Citations
“…These data do not allow prediction of the physicochemical properties and behavior of this acid in systems with other organic solvents. [14][15][16]. Their accurate determination is important for complete understanding the chemical behaviour and the biological activity of ampholytes.…”
Section: Introductionmentioning
confidence: 99%